Nguyen Anh Tu 4

4 · Xeris Biopharma Holdings, Inc. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Xeris Biopharma CMO Nguyen Anh Tu Receives Stock Award

What Happened

Nguyen Anh Tu, Chief Medical Officer of Xeris Biopharma (XERS), was granted a total of 283,455 equity awards on 2026-01-30: 121,293 shares (direct award) and 162,162 shares classified as a derivative award. Each award was granted at $0.00 (no cash paid) and is reported with a total transaction value of $0. These are compensation awards, not open-market purchases or sales.

Key Details

Transaction date: January 30, 2026; Form 4 filed February 2, 2026 (timely filing).
Grant details: 121,293 shares + 162,162 derivative units = 283,455 total awards; per-share price reported $0.00.
Vesting: Footnote indicates these awards are restricted stock units (RSUs) that vest in equal annual installments over three years, subject to continued employment.
Other holdings notes: Footnote also references 3,030 shares acquired 12/31/2025 under the company ESPP and a disclaimer of beneficial ownership (reporting person disclaims beneficial ownership except to extent of pecuniary interest).
The filing excerpt does not list the total shares beneficially owned after these grants in the provided data.

Context

These are compensation grants (awards), which are routine for executives and do not represent open-market buying or selling. The derivative/RSU awards are contingent rights to receive shares upon vesting, not immediate stock sales or option exercises.

Form 4

Period: 2026-01-30

See Remarks

Transactions

Award
Common Stock
[F1][F2]
2026-01-30+121,293→ 424,323 total
Award
Stock Option (Right to Buy)
[F4]
2026-01-30+162,162→ 162,162 total
Exercise: $7.36Exp: 2036-01-30→ Common Stock (162,162 underlying)

Holdings

Footnotes (4)

[F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
[F2]Includes 3,030 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended.
[F3]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
[F4]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-02-02

1 file